A Phase 2, Open-Label, Single-Arm Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma Who Have Received Prior Systemic Anticancer Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Takeda Pharma
- 07 Feb 2019 Planned End Date changed from 31 Mar 2021 to 27 Nov 2020.
- 07 Feb 2019 Planned primary completion date changed from 31 Mar 2021 to 16 Jul 2019.
- 07 Feb 2019 Status changed from recruiting to active, no longer recruiting.